A Risk Stratification Tool for Relapse After Intravenous-To-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases
Preswitch infliximab clearance and fecal calprotectin are accurate predictors of relapse after switching to subcutaneous infliximab. An interactive risk stratification tool facilitates confirmation of a stratified medicine approach to improve infliximab therapy in IBD.
Authors
- Erwin Dreesen (ORCID: https://orcid.org/0000-0002-0785-2930)
- Zhigang Wang (ORCID: https://orcid.org/0000-0001-6415-2044)
- Mathurin Fuméry (ORCID: https://orcid.org/0000-0002-2337-2902)
- Anthony Buisson (ORCID: https://orcid.org/0000-0002-6347-409X)
- Yannick Hoffert (ORCID: https://orcid.org/0000-0002-1631-9484)
- Maria Nachury (ORCID: https://orcid.org/0000-0001-9583-8946)
- Maëva Bazoge
Institutions
- Inserm (FR)
- Université Clermont Auvergne (FR)
- Université de Lille (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- University of Clermont Auvergne (FR)
- Microbe, Intestine, Inflammation and Host Susceptibility (FR)
- Lille Inflammation Research International Center (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Clermont Université (FR)
- Périnatalité & Risques Toxiques (FR)
- Institute for Translational Research in Inflammation (FR)
- Université de Picardie Jules Verne (FR)
- KU Leuven (BE)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.14309/ajg.0000000000003466
- Citations
- 5
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 3.99